title: Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU. A phase II trial.
abstract: Thirty patients with histologically verified malignant supratentorial gliomas were treated with a preirradiation chemotherapy protocol consisting of two courses of intracarotid (i.c.) CDDP, 90 mg/m2, followed by i.v. BCNU, 200 mg/m2. Side effects from therapy were mild and self-limiting; no irreversible retinal or neurologic toxicity could be attributed to i.c. chemotherapy. Of the 27 patients who completed the chemotherapy portion of the protocol, tumor size on postchemotherapy computed tomography (CT) was decreased by greater than 50% in 13% as compared to the postoperative CT scan; in only 4% was the CT scan unequivocally increased in size. Twenty-five (83%) patients completed the entire protocol. Median time to tumor progression and survival in patients who completed the protocol was 53 (range of 13-130+) and 61 (range of 29-130+) weeks, respectively. Twenty-four percent of patients still have not demonstrated tumor progression at intervals greater than 1 year after diagnosis as judged by clinical and radiographic criteria. Tumor recurrences were always contiguous to the original tumor bed. We conclude that preirradiation chemotherapy may be administered safely and with low morbidity. Further study to determine an optimal timing between chemotherapy and radiation therapy is warranted.
authors.affiliation: Department of Neurology, University of Massachusetts Medical Center, Worcester 01655.
authors.forename: L
authors.initials: L
authors.lastname: Recht
authors.forename: R J
authors.initials: RJ
authors.lastname: Fram
authors.forename: G
authors.initials: G
authors.lastname: Strauss
authors.forename: T J
authors.initials: TJ
authors.lastname: Fitzgerald
authors.forename: M
authors.initials: M
authors.lastname: Liepman
authors.forename: R
authors.initials: R
authors.lastname: Lew
authors.forename: S
authors.initials: S
authors.lastname: Kadish
authors.forename: D
authors.initials: D
authors.lastname: Sherman
authors.forename: J
authors.initials: J
authors.lastname: Wilson
authors.forename: J
authors.initials: J
authors.lastname: Greenberger
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D002330:Carmustine / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000097:blood; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D015996:Survival Rate; D014057:Tomography, X-Ray Computed
chemical_list: D002945:Cisplatin; D002330:Carmustine